Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study we tested if autoantibodies against LRP4 are detectable in patients with myasthenia gravis.
|
21814823 |
2012 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A third type of autoantibodies (Lrp4) has been detected to cause myasthenia gravis.
|
21825986 |
2011 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations in MuSK and in genes that function in the MuSK signaling pathway, including Dok-7, cause congenital myasthenia, and autoantibodies to MuSK, Lrp4, and acetylcholine receptors are responsible for myasthenia gravis.
|
23637281 |
2013 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study shows that LRP4-Ab is a pathogenic antibody in MG. LRP4-MG seems to be characterized by mild disease severity and favorable therapeutic effect in contrast with other types of MG.Muscle Nerve 56: 938-942, 2017.
|
28120340 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Low-Density Lipoprotein Receptor-Related Protein 4-Positive Myasthenia Gravis in a Double-Seronegative, Electromyography-Negative Patient.
|
28350570 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focusing on neural agrin, Wnts, muscle-specific tyrosine kinase (a mediator of agrin and Wnts signalings and regulator of trans-synaptic communication), low-density lipoprotein receptor-related protein 4 (the receptor of agrin and Wnts and participant in retrograde signaling), laminin-network (including muscle-derived agrin), extracellular matrix proteins (participating in the synaptic stabilization) and presynaptic receptors (including muscarinic and adenosine receptors), we review the functional structures of the synapse by making reference to immunological pathogenecities in postsynaptic disease, myasthenia gravis.
|
28441759 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
LRP4-MG presented late-onset age, mild symptoms, good therapeutic response, and no thymic changes.
|
28516329 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Double-seropositive myasthenia gravis with acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies associated with invasive thymoma.
|
28694075 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results clearly demonstrate that active immunization of mice with LRP4 proteins causes myasthenia similar to the MG induced by anti-MuSK Abs.
|
28823823 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders.
|
28825343 |
2017 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with dSNMG cortactin<sup>+</sup> MG were negative for anti-striated muscle and anti-LRP4 antibodies.
|
29068555 |
2018 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results from experimental autoimmune MG animal models indicate that anti-LRP4 antibodies are causal to MG. Clinical studies have begun to reveal the significance of the new biomarkers.
|
29377176 |
2018 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The features of LRP4-EAMG are more similar to those of AChR-EAMG, indicating a similar clinical treatment for LRP4- and AChR-positive MG patients, compared to MuSK-positive MG patients.
|
29421431 |
2018 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.
|
30006288 |
2018 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neonatal MG with temporary muscle weakness occurs in 10% of newborn babies where the mother has MG, due to transplacental transfer of antibodies against acetylcholine receptor (AChR), muscle-specific kinase (MuSK) or lipoprotein receptor-related protein 4 (LRP4).
|
30133097 |
2018 |
Myasthenia Gravis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In total, 16 (0.8%) patients with LRP4-MG were found amongst 2172 total patients, including three patients with AChR/LRP4-MG. Additionally, 13 (2.9%) patients with LRP4-MG were found amongst 455 patients with double seronegative MG.
|
31050101 |
2019 |